As Washington’s October 2025 government shutdown drags on, one piece of business left in limbo is the long-anticipated FDA rulemaking to end “self-affirmed” GRAS.
In March, HHS directed FDA to pursue a rule that would eliminate the decades-old practice allowing companies to deem ingredients “generally recognized as safe” without notifying the agency. Industry trackers had expected a Notice of Proposed Rulemaking (NPRM) this month, but with FDA operations curtailed, that timeline is almost certainly slipping.
Still, the direction of travel is clear—and it isn’t backward.
Where Things Stand
Even amid the shutdown, congressional interest hasn’t cooled. H.R. 4958 (119th Congress) remains alive and would require mandatory notification and periodic reassessment of all GRAS determinations. Once the government reopens, the bill and the FDA rulemaking are likely to move in tandem, tightening oversight and increasing public transparency.
Recent industry discussions point to a coming one-two punch:
Formal notification of all GRAS conclusions, ending self-affirmation.
Publication of a public inventory, giving consumers, NGOs, and competitors visibility into ingredient safety evidence.
What It Means for Formulas
Whether action resumes next month or next quarter, companies should anticipate structural change.
Legacy GRAS inputs introduced via self-affirmation may need back-filled notices and publicly accessible data.
New ingredient launches could face delays during the transition as FDA staffing and review systems reset.
Flavors, processing aids, and functional additives will likely draw increased FOIA and NGO attention once filings become public.
What You Can Do Now
Shutdown or not, this is the moment to prepare.
Inventory and prioritize every self-affirmed GRAS ingredient—your own and those from suppliers. Rank by business impact and perceived controversy.
Build or update GRAS dossiers now: safety narrative, manufacturing detail, exposure data, and literature references. A well-organized file today can save months later.
Watch the Hill for movement on H.R. 4958 and related Senate language once appropriations are resolved.
The Big Picture
Even with Washington at a standstill, regulatory momentum rarely reverses. When the lights come back on, GRAS reform will be near the top of FDA’s to-do list—alongside modernized labeling and additive oversight. The window to get ahead of it is right now.
